Characterisation of the antibacterial properties of the recombinant phage endolysins AP50-31 and LysB4 as potent bactericidal agents against Bacillus anthracis. Scientific Reports. 8(1): 18, 2018

Simultaneous RNA-seq based transcriptional profiling of intracellular Brucella abortus and B. abortus-infected murine macrophages. Microbial Pathogenesis. 113: 57-67, 2017

Pharmacokinetics and Tolerance of the Phage Endolysin-Based Candidate Drug SAL200 after a Single Intravenous Administration among Healthy Volunteers. Antimicrob Agents Chemother. 2017 May 24;61(6).

"Evaluating the effectiveness of Streptococcus parauberis bacteriophage Str-PAP-1 as an environmentally friendly alternative to antibiotics for aquaculture" Aquaculture., 468(Part 1):464-470, 2017

“Pharmacokinetics of the phage endolysin-based candidate drug SAL200 in monkeys and its appropriate intravenous dosing period” Clin. Exp. Pharmacol. Physiol. 43(10): 1013-1016, 2016

“The herbal-derived honokiol and magnolol enhances immune response to infection with methicillin-sensitive Staphylococcus aureus (MSSA) and methicillin-resistant S. aureus (MRSA)” Appl. Microbiol. Biotechnol. 99(10): 4387-4396, 2015

“이유자돈에서 Salmonella Typhimurium 감염에 대한 박테리오파지의 방어 효능” 한국가축위생학회지 37(1), 35-43, 2014

“Preclinical safety evaluation of intravenously administered SAL200 containing the recombinant phage endolysin SAL-1 as a pharmaceutical ingredient” Antimicrob. Agents Chemother. 58(4), 2084-2088, 2014

“Effect of gene amplifications in porphyrin pathway on heme biosynthesis in a recombinant Escherichia coli” J. Microbiol. Biotechnol. 23(5), 668-673, 2013

“Antibacterial properties of a pre-formulated recombinant phage endolysin, SAL-1” Int. J. Antimicrob. Agents 41(2), 156-161, 2013